De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

CONMED Beheer

Beheer criteriumcontroles 3/4

De CEO CONMED's is Curt Hartman, benoemd in Jul2014, heeft een ambtstermijn van 10.25 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 7.76M, bestaande uit 12.2% salaris en 87.8% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.28% van de aandelen van het bedrijf, ter waarde $ 6.31M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 8.1 jaar en 9.3 jaar.

Belangrijke informatie

Curt Hartman

Algemeen directeur

US$7.8m

Totale compensatie

Percentage CEO-salaris	12.2%
Dienstverband CEO	10.3yrs
Eigendom CEO	0.3%
Management gemiddelde ambtstermijn	6.8yrs
Gemiddelde ambtstermijn bestuur	9.3yrs

Recente managementupdates

Recent updates

CONMED Corporation's (NYSE:CNMD) Intrinsic Value Is Potentially 97% Above Its Share Price

Jul 17

AirSeal Concerns Have Let Too Much Air Out Of Conmed's Valuation

Jun 21

There Is A Reason CONMED Corporation's (NYSE:CNMD) Price Is Undemanding

Jun 01

Why CONMED Corporation (NYSE:CNMD) Could Be Worth Watching

Apr 18

Is CONMED (NYSE:CNMD) Using Too Much Debt?

Mar 28

CONMED Corporation (NYSE:CNMD) Might Not Be As Mispriced As It Looks After Plunging 26%

Feb 15

US$111: That's What Analysts Think CONMED Corporation (NYSE:CNMD) Is Worth After Its Latest Results

Feb 03

Should You Investigate CONMED Corporation (NYSE:CNMD) At US$107?

Jan 08

Investors Appear Satisfied With CONMED Corporation's (NYSE:CNMD) Prospects

Dec 18

CONMED (NYSE:CNMD) Takes On Some Risk With Its Use Of Debt

Nov 30

Conmed: Sector Derating And A New Competitive Threat Shouldn't Overshadow A Solid Core Business

Oct 28

Is CONMED Corporation (NYSE:CNMD) Potentially Undervalued?

Sep 22

Does CONMED (NYSE:CNMD) Have A Healthy Balance Sheet?

Aug 24

Conmed: Reiterate Buy Rating As Earnings Are Expected To Grow Strongly

Jul 28

Should You Think About Buying CONMED Corporation (NYSE:CNMD) Now?

Jun 08

These 4 Measures Indicate That CONMED (NYSE:CNMD) Is Using Debt Extensively

May 17

Estimating The Intrinsic Value Of CONMED Corporation (NYSE:CNMD)

Apr 28

Why CONMED Corporation (NYSE:CNMD) Could Be Worth Watching

Mar 10

Here's Why CONMED (NYSE:CNMD) Has A Meaningful Debt Burden

Feb 14

CONMED Non-GAAP EPS of $0.42 misses by $0.48, revenue of $250.9M misses by $51.58M

Feb 02

Estimating The Intrinsic Value Of CONMED Corporation (NYSE:CNMD)

Jan 24

ConMed: Still Fairly Priced, Turning More Constructive

Dec 09

At US$83.60, Is CONMED Corporation (NYSE:CNMD) Worth Looking At Closely?

Nov 18

Conmed withdraws FY22 guidance on software implementation-related disruption

Nov 15

CONMED (NYSE:CNMD) Has A Pretty Healthy Balance Sheet

Oct 11

ConMed: Fairly Priced At Pre-Pandemic Market Cap

Sep 21

CONMED (NYSE:CNMD) Has Announced A Dividend Of $0.20

Sep 03

CONMED (NYSE:CNMD) Has Affirmed Its Dividend Of $0.20

Aug 18

CONMED declares $0.20 dividend

Aug 11

Analyse CEO-vergoeding

Hoe is Curt Hartman's beloning veranderd ten opzichte van CONMED's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	US$99m
Mar 31 2024	n/a	n/a	US$82m
Dec 31 2023	US$8m	US$950k	US$64m
Sep 30 2023	n/a	n/a	US$58m
Jun 30 2023	n/a	n/a	US$88m
Mar 31 2023	n/a	n/a	-US$94m
Dec 31 2022	US$8m	US$946k	-US$81m
Sep 30 2022	n/a	n/a	-US$83m
Jun 30 2022	n/a	n/a	-US$114m
Mar 31 2022	n/a	n/a	US$68m
Dec 31 2021	US$9m	US$918k	US$63m
Sep 30 2021	n/a	n/a	US$62m
Jun 30 2021	n/a	n/a	US$54m
Mar 31 2021	n/a	n/a	US$13m
Dec 31 2020	US$6m	US$888k	US$10m
Sep 30 2020	n/a	n/a	US$311k
Jun 30 2020	n/a	n/a	US$431k
Mar 31 2020	n/a	n/a	US$34m
Dec 31 2019	US$6m	US$842k	US$29m
Sep 30 2019	n/a	n/a	US$29m
Jun 30 2019	n/a	n/a	US$28m
Mar 31 2019	n/a	n/a	US$31m
Dec 31 2018	US$5m	US$791k	US$41m
Sep 30 2018	n/a	n/a	US$72m
Jun 30 2018	n/a	n/a	US$73m
Mar 31 2018	n/a	n/a	US$71m
Dec 31 2017	US$3m	US$753k	US$55m

Compensatie versus markt: De totale vergoeding ($USD 7.76M ) Curt } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 5.54M ).

Compensatie versus inkomsten: De vergoeding van Curt is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Curt Hartman (60 yo)

10.3yrs

Tenure

US$7,764,615

Compensatie

Mr. Curt R. Hartman has been Chairman of the Board at CONMED Corporation since May 21, 2020. Mr. Hartman has been the Chief Executive Officer and President of CONMED Corporation since November 09, 2014. Mr...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Curt Hartman	Chairman of the Board	10.3yrs	US$7.76m	0.28% $ 5.8m
Todd Garner	Executive VP	6.8yrs	US$2.87m	0.00074% $ 15.2k
Patrick Beyer	Chief Operating Officer	less than a year	US$3.30m	0.035% $ 719.5k
Stanley Peters	President of Advanced Surgical & Advanced Endoscopic Technologies	9.8yrs	US$2.00m	0.0048% $ 99.0k
Richard Glaze	Chief Information Officer	no data	geen gegevens	geen gegevens
Peter Shagory	Executive Vice President of Strategy & Corporate Development	9.4yrs	geen gegevens	0.012% $ 247.2k
Shanna Cotti-Osmanski	Executive VP of Information Technology & CIO	4.6yrs	geen gegevens	geen gegevens
John Ferrell	Executive Vice President of Human Resources	1.8yrs	geen gegevens	0.0023% $ 46.8k
Daniel Jonas	Special Counsel & Corporate Secretary	6.4yrs	US$1.55m	0.044% $ 896.5k
David Murray	President of ConMed Electrosurgery	20.3yrs	US$572.33k	geen gegevens
Johonna Pelletier	VP of Tax & Treasurer	9.5yrs	geen gegevens	0.0043% $ 87.7k
Kimberly Lockwood	Interim Corporate Controller	less than a year	geen gegevens	geen gegevens

6.8yrs

Gemiddelde duur

56yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van CNMD is doorgewinterd en ervaren (gemiddelde ambtstermijn van 8.1 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Curt Hartman	Chairman of the Board	10.6yrs	US$7.76m	0.28% $ 5.8m
John Workman	Independent Director	9.3yrs	US$257.37k	0.066% $ 1.4m
David Bronson	Independent Director	9.3yrs	US$264.87k	0.054% $ 1.1m
Brian Concannon	Independent Director	11.3yrs	US$257.37k	0.031% $ 641.7k
LaVerne Council	Independent Director	4.8yrs	US$257.37k	0.012% $ 237.7k
Martha Aronson	Lead Independent Director	8.7yrs	US$292.37k	0.045% $ 926.5k
Charles Farkas	Independent Director	10.3yrs	US$249.87k	0.066% $ 1.4m
Barbara Schwarzentraub	Independent Director	5.1yrs	US$264.87k	0.017% $ 353.3k

9.3yrs

Gemiddelde duur

64yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van CNMD wordt beschouwd als ervaren (gemiddelde ambtstermijn 9.3 jaar).

CONMED Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

CONMED Corporation Announces Termination of Stanley W. (Bill) Peters as President, Advanced Surgical & Advanced Endoscopic Technologies, Effective August 31, 2024

Insider notifies of intention to sell stock

CONMED Corporation, Annual General Meeting, May 22, 2024

Insider exercised options and sold US$721k worth of stock

Insider notifies of intention to sell stock

Insider notifies of intention to sell stock

Recent updates

CONMED Corporation to Report Q3, 2024 Results on Oct 30, 2024

Should You Investigate CONMED Corporation (NYSE:CNMD) At US$71.92?

Why We're Not Concerned About CONMED Corporation's (NYSE:CNMD) Share Price

Upcoming dividend of US$0.20 per share

CONMED Corporation Announces Termination of Stanley W. (Bill) Peters as President, Advanced Surgical & Advanced Endoscopic Technologies, Effective August 31, 2024

CONMED (NYSE:CNMD) Is Paying Out A Dividend Of $0.20

Second quarter dividend of US$0.20 announced

Consensus EPS estimates increase by 10%, revenue downgraded

Price target decreased by 8.8% to US$84.25

CONMED Corporation Revises Earnings Guidance for the Full Year 2024

CONMED Corporation's (NYSE:CNMD) Intrinsic Value Is Potentially 97% Above Its Share Price

CONMED Corporation to Report Q2, 2024 Results on Jul 31, 2024

AirSeal Concerns Have Let Too Much Air Out Of Conmed's Valuation

Insider notifies of intention to sell stock

Upcoming dividend of US$0.20 per share

There Is A Reason CONMED Corporation's (NYSE:CNMD) Price Is Undemanding

First quarter dividend of US$0.20 announced

CONMED Corporation Declares Quarterly Cash Dividend, Payable on July 5, 2024

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

CONMED Corporation Revises Earnings Guidance for the Full Year 2024

Why CONMED Corporation (NYSE:CNMD) Could Be Worth Watching

CONMED Corporation, Annual General Meeting, May 22, 2024

CONMED Corporation to Report Q1, 2024 Results on Apr 24, 2024

Is CONMED (NYSE:CNMD) Using Too Much Debt?

Insider exercised options and sold US$721k worth of stock

Upcoming dividend of US$0.20 per share

CONMED Corporation Declares Quarterly Cash Dividend, Payable on April 5, 2024

CONMED Corporation (NYSE:CNMD) Might Not Be As Mispriced As It Looks After Plunging 26%

US$111: That's What Analysts Think CONMED Corporation (NYSE:CNMD) Is Worth After Its Latest Results

Full year 2023 earnings: EPS misses analyst expectations

CONMED Corporation Provides Financial Guidance for the Full Year 2024

Investor sentiment deteriorates as stock falls 17%

Should You Investigate CONMED Corporation (NYSE:CNMD) At US$107?

Investors Appear Satisfied With CONMED Corporation's (NYSE:CNMD) Prospects

CONMED Corporation Announces Quarterly Cash Dividend, Payable on January 5, 2024

CONMED (NYSE:CNMD) Takes On Some Risk With Its Use Of Debt

Consensus EPS estimates fall by 11%

Conmed: Sector Derating And A New Competitive Threat Shouldn't Overshadow A Solid Core Business

Price target decreased by 9.5% to US$123

Third quarter 2023 earnings: EPS misses analyst expectations

CONMED Corporation Updates Third Quarter Guidance for 2023

CONMED Corporation to Report Q3, 2023 Results on Oct 25, 2023

Is CONMED Corporation (NYSE:CNMD) Potentially Undervalued?

Upcoming dividend of US$0.20 per share at 0.7% yield

Does CONMED (NYSE:CNMD) Have A Healthy Balance Sheet?

CONMED Corporation Announces Quarterly Cash Dividend, Payable on October 5, 2023

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Conmed: Reiterate Buy Rating As Earnings Are Expected To Grow Strongly

CONMED Corporation Revises Earnings Guidance for the Full Year 2023

CONMED Corporation to Report Q2, 2023 Results on Jul 26, 2023

Insider notifies of intention to sell stock

Should You Think About Buying CONMED Corporation (NYSE:CNMD) Now?

Upcoming dividend of US$0.20 per share at 0.6% yield

CONMED Corporation Announces Quarterly Cash Dividend, Payable on July 5, 2023

Insider notifies of intention to sell stock

These 4 Measures Indicate That CONMED (NYSE:CNMD) Is Using Debt Extensively

Insider recently sold US$166k worth of stock

Price target increased by 13% to US$126

Estimating The Intrinsic Value Of CONMED Corporation (NYSE:CNMD)

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Chairman of the Board recently sold US$464k worth of stock

Executive VP & CFO exercised options and sold US$1.2m worth of stock

Why CONMED Corporation (NYSE:CNMD) Could Be Worth Watching

Upcoming dividend of US$0.20 per share at 0.8% yield

Special Counsel & Corporate Secretary exercised options and sold US$283k worth of stock

Here's Why CONMED (NYSE:CNMD) Has A Meaningful Debt Burden

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target increased by 11% to US$110

CONMED Corporation Provides Earnings Guidance for the Full Year 2023